Explore more publications!
Illinois Tech Journal
Got News to Share?

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX
3 hours ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX

Indeterminate GlobeNewswire, Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Byrna Technologies Inc. - BYRN
2 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Byrna Technologies Inc. - BYRN

Indeterminate GlobeNewswire, Inc.
ImPact Biotech Announces Upcoming Data Presentations for Padeliporfin VTP at AUA and ASCO 2026
9 hours ago

ImPact Biotech Announces Upcoming Data Presentations for Padeliporfin VTP at AUA and ASCO 2026

Indeterminate GlobeNewswire, Inc.
Strata Decision Technology Releases 2026 Healthcare Financial Outlook Report, Highlighting Policy Pressures and Renewed Focus on Disciplined Performance
10 hours ago

Strata Decision Technology Releases 2026 Healthcare Financial Outlook Report, Highlighting Policy Pressures and Renewed Focus on Disciplined Performance

Indeterminate GlobeNewswire, Inc.
Nobel-Potential Discovery from VectorBuilder Scientists Reveals Fundamental Mechanisms of Development
13 hours ago

Nobel-Potential Discovery from VectorBuilder Scientists Reveals Fundamental Mechanisms of Development

Indeterminate GlobeNewswire, Inc.
Car Detailing Service Market Size worth USD 65.49 Billion by 2032, Exclusive Report by Maximize Market Research
17 hours ago

Car Detailing Service Market Size worth USD 65.49 Billion by 2032, Exclusive Report by Maximize Market Research

Neutral EIN Presswire
Rgenta Therapeutics Announces RGT-61159 Clinical Poster Presentation at the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
2 hours ago

Rgenta Therapeutics Announces RGT-61159 Clinical Poster Presentation at the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Indeterminate GlobeNewswire, Inc.
Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
2 hours ago

Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting

Indeterminate GlobeNewswire, Inc.
Solidion Technology Joins Forces with Hilco Global to Monetize Patent Portfolio
Apr. 20, 2026

Solidion Technology Joins Forces with Hilco Global to Monetize Patent Portfolio

Neutral EIN Presswire
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
2 hours ago

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting

Indeterminate GlobeNewswire, Inc.
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
2 hours ago

ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026

Indeterminate GlobeNewswire, Inc.
TheJembe Launches Multicultural Intelligence Services to Help Brands Navigate a Changing Market
3 hours ago

TheJembe Launches Multicultural Intelligence Services to Help Brands Navigate a Changing Market

Neutral EIN Presswire
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
2 hours ago

Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Indeterminate GlobeNewswire, Inc.
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
3 hours ago

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

Indeterminate GlobeNewswire, Inc.
CAHME Announces the Initial Accreditation of the University of Illinois Urbana-Champaign, MHA
Apr. 19, 2026

CAHME Announces the Initial Accreditation of the University of Illinois Urbana-Champaign, MHA

Neutral EIN Presswire
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
9 hours ago

Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

Indeterminate GlobeNewswire, Inc.
Remix Therapeutics Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting
8 hours ago

Remix Therapeutics Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting

Indeterminate GlobeNewswire, Inc.
Aquatics Safety Experts Address the ‘National Distraction Epidemic’ This Summer
5 hours ago

Aquatics Safety Experts Address the ‘National Distraction Epidemic’ This Summer

Indeterminate GlobeNewswire, Inc.
ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026
8 hours ago

ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026

Indeterminate GlobeNewswire, Inc.
Hanmi Reports 2026 First Quarter Results
3 hours ago

Hanmi Reports 2026 First Quarter Results

Indeterminate GlobeNewswire, Inc.
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions